Hoth Therapeutics, Inc. (NASDAQ: HOTH) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of novel treatments to help patients live better lives. Shares of the biopharma company are rallying 27% through early trading on Monday, October 31, 2022. Over the past three months, Hoth Therapeutics has seen average daily volume of 13,040 shares. However, volume of 1.7 million shares or dollar volume of around $12.53 million, has already exchanged hands through early trading.
Shares of Hoth Therapeutics are gaining after the company announced results from its Phase 1B clinical trial of BioLexa for the treatment of mild-to-moderate atopic dermatitis. Utilizing the SCORAD scale to assess a patient’s severity, the clinical trial showed all patients experiencing improvement compared to their day-one scores. Using the EASI scale, 100% of patients saw clinically-relevant improvement of over 50% compared to their initial day-one readings. On the SCORAD scale, 60% of patients saw clinically relevant improvement. The Phase 1B results demonstrate that BioLexa can be effective to treat the underlying staphylococcal infection.
The total surface area of atopic dermatitis found on patients being treated with BioLexa decreased in 71% of patients. Within the patients that experienced relief, total reduction ranged from 37.5% to 71.4%.
BioLexa was well-tolerated during the clinical trial and did not cause any adverse events or drug-related reactions. Overall, over 50% of patients said they experienced an improvement on their quality of life after the results showed improvement to their atopic dermatitis.
Robb Knie, Chief Executive Officer of Hoth Therapeutics, stated, “Today’s positive results give us even more confidence that BioLexa can help provide relief from atopic dermatitis in patients, without the harmful long-term effects of corticosteroids and other side effects that many patients suffer with today’s choice of approved therapeutics.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
